Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Gastrointestinal 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Genitourinary 1Dermatologic 1CNS 1Breast 1

Conditions

Ovarian Neoplasms 6Advanced Solid Tumours 5Squamous Cell Carcinoma of Head and Neck 4Small Cell Lung Carcinoma 4Uterine Cervical Neoplasms 3Neoplasms 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Glioblastoma 3Fallopian Tube Neoplasms 3Uterine Neoplasms 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Solid Tumors 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Lymphoma 2Hematologic Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Advanced Malignant Solid Neoplasm 2Vaginal Neoplasms 1Urinary Bladder Neoplasms 1Triple-negative Metastatic Breast Cancer 1Tongue Neoplasms 1Thyroid Neoplasms 1Rhabdomyosarcoma 1

Interventions

Oxaliplatin 290Capecitabine 206Fluorouracil 181Cisplatin 168Docetaxel 138S 1 (combination) 132Paclitaxel 121Leucovorin 116Irinotecan 106pembrolizumab 103Trastuzumab 71apatinib 56Nivolumab 56sintilimab 45Drug Therapy 43Surgical Procedures, Operative 37Radiotherapy 37Bevacizumab 37Ramucirumab 34titanium silicide 31Hyperthermic Intraperitoneal Chemotherapy 30Epirubicin 30Carboplatin 30tislelizumab 28Cyclophosphamide 27XELOX 24Tegafur 23Folfox protocol 22Albumin-Bound Paclitaxel 22camrelizumab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Stomach Neoplasms × adavosertib × Clear all
NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT01047007 2023-09-21

A Dose Escalation Study of Adavosertib(MK1775) in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005

Merck Sharp & Dohme LLC

Phase 1 Terminated
11 enrolled 10 charts
GastrointestinalHead & Neck

Esophageal Neoplasms, Head and Neck Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡